"Not So Different" Episode 10: The Patient Perspective on Biosimilars
June 3rd 2018Recently, Louis Tharp, the cofounder and executive director of the patient advocacy organization the Global Healthy Living Foundation, visited our studios in New Jersey to talk about how high drug costs impact patients with rheumatic diseases, and how biosimilars can be part of the solution. Our podcast this week features a portion of our discussion about biologics, biosimilars, and the patient’s viewpoint.
"Not So Different" Episode 9: Biosimilars and Expanded Access to Cancer Treatment
May 20th 2018This week on “Not So Different,” our guest is Ali McBride, PharmD, MS, BCPS. McBride is pharmacist who serves as the Clinical Coordinator for Hematology and Oncology at The University of Arizona Cancer Center. He’s also the lead author of a recent study that showed that using biosimilar filgrastim can expand patients’ access to treatment with obinutuzumab.
"Not So Different" Episode 8: Medicare and Biosimilars
May 6th 2018This week on the podcast, we’re pleased to welcome our guest, Leigh Purvis, MPA. Purvis is the director of health services research at AARP’s public policy institute. Her work focuses on a variety of prescription drug and mental health-related issue, with an emphasis on prescription drug pricing, biologic drugs, and prescription drug coverage under Medicare.
"Not So Different" Episode 7: Oncology Biosimilars
April 22nd 2018Last time on the podcast, we spoke with a practicing rheumatologist about his experience with biosimilars so far, but one of the most exciting prospects on the biosimilars horizon is the market entry of 2 approved anticancer biosimilars: trastuzumab and bevacizumab. This week, we’re delving into the world of supportive care and anticancer biosimilars with an oncology expert, Robert M. Rifkin, MD, FACP.
"Not So Different" Episode 6: The Nebraska Rheumatology Society
April 8th 2018Today, we’re talking about state-level legislation concerning the substitution of interchangeable biosimilars, and how 1 specific piece of biosimilars-focused legislation led Marcus Snow, MD, to found the Nebraska Rheumatology Society.
"Not So Different" Episode 5: Policy and Biosimilars
March 20th 2018“If legislators want to be able to tell their constituents that they acted on drug prices this year, this is the vehicle to do it. There is nothing else with this kind of support and with this kind of impact sitting before legislators right now,” said Christine Simmon, JD, executive director of the Biosimilars Council, about the bipartisan CREATES Act.
"Not So Different" Episode 3: Pricing
March 4th 2018Our guest on this episode of "Not So Different" is Jim Van Lieshout, MBA, who joined us by phone from Colorado to discuss the many considerations that biosimilar developers must take into account when they determine how to price their products to compete in the marketplace.